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Escherichia coli is a major udder pathogen causing clinical mastitis in dairy cattle and its heat stable endotoxin in powdered infant
formula milk is a potential risk factor in neonatal infections. Cephalosporins are frequently used for treatment of mastitis caused
by mastitis; however, use of these antimicrobials may induce antimicrobial resistance in E. coli. The objective of this study was to
explore the in vitro effect of subminimum inhibitory concentrations (sub-MIC) of cefalotin (CF) and ceftazidime (CAZ) on the
morphology, antimicrobial resistance, and endotoxin releasing characteristics of 3 E. coli isolates recovered from bovine clinical
mastitis. The parent E. coli isolates, which were susceptible to CF and CAZ, were exposed to CF or CAZ separately at sub-MIC
levels to produce 9 generations of induced isolates. Colonies of the CAZ-induced isolates from all 3 parent E. coli were smaller on
blood agar and the bacteria became filamentous, whereas the CF-induced isolates did not demonstrate prominent morphological
changes. After induction by CF or CAZ, many induced isolates showed resistance to cefoxitin, CAZ, CF, kanamycin, ampicillin,
and amoxicillin/clavulanic acidwhile their parent isolates were susceptible to these antimicrobials. Notably, 5 CAZ-induced isolates
from the same parent isolate were found to produce extended-spectrum beta-lactamase (ESBL) though none of the tested ESBL
related genes could be detected. All CAZ-induced isolates released more endotoxin with a higher release rate, whereas endotoxin
release of CF-induced E. coli isolates was not different from parent isolates. The exposure of cephalosporins at sub-MIC levels
induced resistant Escherichia coli. We inferred that cephalosporins, especially CAZ, should be used prudently for treatment of
clinical E. colimastitis.
1. Introduction
Mastitis is one of the most common and costly diseases for
the dairy industry worldwide. Mastitis also affects animal
welfare and is a frequent reason that cows are culled [1]. Treat-
ment of mastitis accounts for the majority of antimicrobials
administered to dairy cows [2, 3]. Gram-negative bacteria,
mostly coliforms, including Escherichia coli, Klebsiella spp.,
and Enterobacter spp., cause a high proportion of all clinical
mastitis (CM) cases [4–6]. Escherichia coli is the most
common Gram-negative species causing CM in dairy cattle
[4, 6, 7]. The endotoxin of E. coli, lipopolysaccharide (LPS),
can remain biologically active in powdered infant formula
milk because it is heat stable at 100∘C and, therefore,may pose
a potential risk to formula fed neonates [8].
The efficacy and necessity of antimicrobial therapy for
treatment of E. coli mastitis are still a topic of debate [9].
However, fluoroquinolones and cephalosporins, particularly
3rd and 4th generation products, are the only antimicrobials
for which there is supporting evidence of beneficial effects in
treatment of E. colimastitis [10, 11]. It is noteworthy that these
2 classes of antimicrobial agents are also important drugs
for human health. The prevalence of resistance against these
important antibiotics, particularly in E. coli, is increasing
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worldwide in veterinary and human medicine [12–14]. The
2 main factors involved in development of antimicrobial
resistance in bacteria are the presence of resistance genes
and selective pressure of antimicrobial agents, especially
if suboptimal doses are administered [15]. Currently, very
limited studies have been conducted to elucidate the influ-
ence of cephalosporin dosage on induction of antimicrobial
resistance in E. coli isolated from CM. First-generation
cephalosporins are less critical for human health, although
they primarily have a Gram-positive spectrum, with limited
activity against Gram-negative bacteria [16, 17].
Induction of antimicrobial resistance in E. coli has been
characterized by changes in morphology, including filamen-
tation, which is likely to protect the bacteria from deleterious
effects of antimicrobials [18, 19].There is also strong evidence
that antimicrobials may enhance endotoxin release from E.
coli, which could exacerbate symptoms of CM [18].
The main objective of this study was, therefore, to deter-
mine in vitro effects of sub-MIC exposure of cefalotin (CF)
or ceftazidime (CAZ) on 3 E. coli isolates recovered from
bovine CMcases. Characteristics such as colonymorphology,
antimicrobial susceptibility profile, and release of endotoxin
from E. coli isolates recovered after induction were investi-
gated.
2. Materials and Methods
2.1. Escherichia coli Isolates. Quarter milk samples (n=1252)
were collected from July 2015 to May 2016 from dairy cows
with CM from various dairy herds located in 16 Chinese
provinces [7]. In total, 153 E. coli isolates were recovered,
of which 36 produced extended-spectrum beta-lactamase
(ESBL). More details on the origin and characteristics of the
E. coli isolates are described [12]. All isolates were tested
for resistance to CF (30 휇g) and CAZ (30 휇g) using the
Kirby-Bauer disk diffusion method, with clinical breakpoints
following recommendations of the Clinical and Laboratory
Standards Institute [20]. Three E. coli isolates, subsequently
referred to as E4, E11, and E21, were selected from 3 provinces
(Beijing, Shanghai, and Gansu) and used as parent E. coli
isolates in this study. The 3 isolates were susceptible to CF
and CAZ, did not produce ESBL, and did not carry any of
the tested ESBL encoding genes (data not shown).
2.2. Experimental Design. All steps of the experiment were
carried out in triplicate. A single colony was inoculated
into 20 mL trypticase soy broth (TSB; BD, Franklin Lake,
NJ) and incubated for 12 h at 37∘C. Then, 200 휇L of the
bacterial suspension (0.5 McFarland) was inoculated into
20 mL Mueller-Hinton broth (Luqiao, Beijing, China) to
which 1/2 of the MIC was added for CF and CAZ separately
and incubated for 24 h at 37∘C. Subsequently, the bacterial
suspension was centrifuged (6000 × g, 25∘C, 5 min) (Anting,
Shanghai, China) and the pellet resuspended in a solution
containing 1.4 mL TSB and 0.6 mL glycerol (Luqiao, Beijing,
China) and stored pending further processing.These induced
isolates (i.e., first generation of growth) are further referred
to as CF-1 groups (E4-CF-1, E11-CF-1, and E21-CF-1). The
MIC values for CF versus CF-1 groups were determined,
and 1/2 of the MIC of CF was again dissolved in Mueller-
Hinton broth (Luqiao, Beijing, China) containing 1.5 x 106
CFU/mL of CF-1 groups. After 24 h of incubation at 37∘C, the
2nd generation induced mutant was obtained and identified
as CF-2 group. The same steps were repeated another 7
times. Induced E. coli isolates recovered after subsequent
induction were designated CF-3, CF-4, CF-5, CF-6, CF-7,
CF-8, and CF-9. Escherichia coli isolates were recovered after
induction with CAZ, using procedures identical to those
mentioned above for CF. Isolates recovered after induction
were identified as CAZ-1, CAZ-2, CAZ-3, CAZ-4, CAZ-5,
CAZ-6, CAZ-7, CAZ-8, and CAZ-9 (E4-CAZ, E11-CAZ, and
E21-CAZ). Parent isolates and all induced isolates recovered
after induction were stored in 30% glycerol at -80∘C pending
further processing. When MICs of the parent E. coli and
induced isolates were determined, E. coli ATCC 25922 was
used as a control strain. The CLSI breakpoints for CF were
≤ 8 휇g/mL (susceptible), 16 휇g/mL (intermediate), and ≥ 32
휇g/mL (resistant). In case of CAZ, breakpoints for ceftiofur
(≤ 2 휇g/mL = susceptible, 4 휇g/mL = intermediate, and ≥ 8
휇g/mL = resistant) were used [20].
2.3. Morphological Observations. Stored isolates were recov-
ered by streaking 100 휇L of suspension on tryptone soya agar
(TSA; Luqiao, Beijing, China) supplemented with 5% sheep
blood and incubated for 24 h at 37∘C. A pure growth was
picked and streaked on anewTSAplate. Shape, size, and color
of colonies were recorded. A single colony from agar was
stained using the Gram-staining method and morphology
examined with an optical microscope (Olympus, Tokyo,
Japan).
2.4. Antimicrobial Susceptibility Testing. Antimicrobial sus-
ceptibility of the parent E. coli and isolates recovered after
induction was determined using Mueller-Hinton agar (BD,
Franklin Lakes, NJ) against 9 antimicrobial agents using the
standard Kirby-Bauer disk diffusion method according to
CLSI recommendations [20]. Inhibition zone diameter (mm)
wasmeasured using a ruler.The panel of antimicrobial agents
consisted of ampicillin (10 휇g), amoxicillin/clavulanic acid
(20/10 휇g), CAZ (30 휇g), CF (30 휇g), cefepime (30 휇g),
cefoxitin (30 휇g), gentamicin (10 휇g), kanamycin (30 휇g), and
amikacin (30 휇g). For these antimicrobial agents, breakpoints
for cefepime and cefoxitin referred to E. coli isolates from
humans. Escherichia coli ATCC 25922 and Enterobacter cloa-
cae CMCC45301 were used as quality control strains.
2.5. Detection of ESBL Production. Parent isolates and all iso-
lates recovered after induction were screened onMacConkey
agar containing cefotaxime (1 mg/L) for ESBL-production.
Presumptive ESBL-producing isolates, if any, were further
confirmed by the double-disc synergy test, following recom-
mendations of the CLSI [20], using antimicrobial discs of
cefotaxime (30 휇g), cefotaxime plus clavulanic acid (30/10
휇g), CAZ (30 휇g), and CAZ plus clavulanic acid (30/10
휇g). Production of ESBL was considered positive if the
inhibition zone of cefotaxime plus clavulanic acid or CAZ
plus clavulanic acid was ≥ 5 mm larger than their respective
single discs [20].Escherichia coliATCC25922 (ESBL-negative
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Table 1: Primers used to detect extended spectrum beta-lactamase encoding genes.
Genes Primer sequence (5耠 to 3耠) Amplicon size (bp)
푏푙푎CTX-M CGC TTT GCG ATG TGC AG 550
ACC GCG ATA TCG TTG GT
푏푙푎CTX-M-1 GTT ACA ATG TGT GAG AAG CAG 1041
CCG TTT CCG CTA TTA CAA AC
푏푙푎CTX-M-2 ATG ATG ACT CAG AGC ATT CGC CGC 876
TCA GAA ACCGTG GGT TAC GAT TTT
푏푙푎CTX-M-9 GTG ACA AAGAGA GTG CAA CGG 857
ATG ATT CTC GCC GCT GAA GCC
푏푙푎CTX-M-15 CAC ACG TGG AAT TTA GGG ACT 995
GCC GTC TAAGGC GAT AAA CA
푏푙푎TEM TTC TTG AAGACG AAAGGG C 1150
ACG CTC AGT GGA ACG AAA AC
푏푙푎SHV CAC TCA AGG ATG TAT TGT G 885
TTA GCG TTG CCA GTG CTC G
푏푙푎OXA ACA CAA TAC ATA TCA ACT TCG C 813
AGT GTG TTT AGA ATG GTG ATC
strain) and Klebsiella pneumoniae ATCC 700603 (ESBL-
positive strain) were used as reference strains.
2.6. Detection of ESBL-Related Genes. Bacterial DNA from
E. coli was isolated using the Bacterial DNA Extraction
Kit (Transgen, Beijing, China) according to the manufac-
turer’s instructions. A PCR assay was conducted to detect
the presence of 푏푙푎CTX-M, 푏푙푎CTX-M-1, 푏푙푎CTX-M-2, 푏푙푎CTX-M-9,
푏푙푎CTX-M-15, 푏푙푎SHV, 푏푙푎TEM, and 푏푙푎OXA genes, as described
[21, 22] with minor modifications. The reaction mixture
(20 휇L) consisted of 10 휇L of TaqMix (Transgen, Beijing,
China), 1 휇L of template DNA, 0.5 휇L of each primer (10 휇M;
Sunbiotech, Beijing, China), and 8 휇L of ultra-pure distilled
water. Initial denaturation at 94∘C for 5 min was followed by
35 cycles of amplification at 94∘C for 45 s, annealing at 55∘C
for 30 s, and extension at 72∘C for 60 s, and a final step with
extension at 72∘C for 10 min. The PCR products were sepa-
rated on a 2% agarose gel. Subsequently, PCR products were
purified by TIANquick Midi Purification Kit (TIANGEN,
Beijing, China) and then bidirectionally sequenced using the
same primers by ABI 3730 sequencer (Applied Biosystems,
Foster City, CA). Gene sequences were aligned with BLASTN
software (http://www.ncbi.nlm.nih.gov/BLAST/) and com-
pared to sequences available in GenBank. Klebsiella pneu-
moniae ATCC 700603 (ESBL-positive strain) and ddH2O,
without template DNA, were used as positive and negative
controls, respectively, in all PCR assays. Primers used in this
study are presented in Table 1.
2.7. Detection of Endotoxin Release. Isolates recovered after
induction with CF or CAZ, as well as parent isolates, were
used for this part of the study. Frozen bacteria were thawed at
37∘C for 60min. Ten 휇L of suspension was streaked onto TSA
supplemented with 5% sheep blood and incubated for 24 h at
37∘C. A single colony was picked from the agar, inoculated
into 10 mL of TSB, and incubated for 18 h at 37∘C. Bacterial
counts were measured using the 10-fold dilution method.
Subsequently, bacterial solutions were diluted to 106 CFU/mL
using TSB and bacteria were cultured aerobically at 37∘C. At
various time points (0, 2, 4, 6, 8, and 10 h), aliquots were
collected and endotoxin release capability quantified. Briefly,
aliquots were collected and centrifuged at 6,000 × g for 15
min.The supernatant of each aliquot was collected and stored
at -20∘C until further processing. Endotoxin concentration
wasmeasured using an enzyme-linked immunosorbent assay
(ELISA) commercial kit (Sigma, St. Louis, MO). Each step
was performed following the manufacturer’s instructions. All
experiments were performed in triplicate.
2.8. Statistical Analyses. Associations between endotoxin re-
lease and exposure to sub-MICs of CF and CAZ were
determined by fitting a mixed effects linear regression model
using replicate (n = 3) as the random effect with the lme4
package (Bates et al., 2017) in R version 3.3.0 (R Core Team).
A P-value < 0.05 was considered statistically significant.
Data were first visually examined to understand associations
between time and endotoxin release. Due to the sigmoidal
nature of the association, data were normalized by taking
the natural logarithm of endotoxin release, which resulted
in a more clearly parabolic association between incubation
time and endotoxin release. Higher degree terms for time
were included to more accurately adjust for this parabolic
relationship and isolate effects of treatment and generation
of isolate on endotoxin release. The final model included
treatment (CF, CAZ, or control) and an interaction with
generation (ranging from 1 to 9) as independent variables,
with an adjustment for incubation time modelled with cubic
and quadratic terms, as higher degree polynomial terms did
not increase model fit as determined by P-value and change
in restricted maximum likelihood criterion.
3. Results
3.1. MICs of Cefalotin and Ce
azidime. TheMICs of CF and
CAZ for the parent E. coli isolates were 0.5-4 휇g/mL and
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Table 2: Minimal inhibitory concentrations of cefalotin and ceftazidime against Escherichia coli isolates.
MIC of E. coli isolates (휇g/mL)
Isolate Antimicrobial Parent type -1∗ -2 -3 -4 -5 -6 -7 -8 -9
E4 Cefalotin† 4 8 32# 80# 240# 240# 320# 320# 320# 320#
Ceftazidime‡ 0.125 0.25 2 4 16# 16# 32# 32# 64# 128#
E11 Cefalotin 0.5 2 16 32# # # # # # #
Ceftazidime 1 4 8# 8# 16# 32# 32# 64 128# 128#
E21 Cefalotin 2 8 16 16 # # # # # #
Ceftazidime 0.5 1 4 4 8# 16# 16# 32# 32# 64#
No mark: susceptible or intermediate to cefalotin or ceftazidime; #: resistant to cefalotin or ceftazidime. Breakpoints for cefalotin were as follows: susceptible
⩽ 8 휇g/mL, intermediate 16 휇g/mL, and resistant ⩾ 32 휇g/mL. Breakpoints for ceftazidime were as follows: susceptible ⩽ 2 휇g/mL, intermediate 4 휇g/mL, and
resistant ⩾ 8 휇g/mL.
∗Escherichia coli isolates at various generations that were induced by cefalotin or ceftazidime.
†MIC values of cefalotin were determined for E. coli isolates induced by cefalotin.
‡MIC values of ceftazidime were determined for E. coli isolates induced by ceftazidime.
Table 3: Antimicrobial susceptibility profiles of the Escherichia coli isolates recovered after induction with cefalotin.
Resistant E. coli isolates
Antimicrobial Derived from E4 Derived from E11 Derived from E21
Cefoxitin CF-3/-4/-5/-6/-7/-8/-9 CF-5/-6/-7/-8/-9 CF-5/-6/-7/-8/-9
Ceftazidime CF-5/-6/-7/-8/-9 CF-5/-6/-7/-8/-9 CF-7/-8/-9
Ampicillin CF-4/-5/-6/-7/-8/-9 CF-3/-4/-5/-6/-7/-8/-9 CF-6/-7/-8/-9
Amoxicillin/clavulanic acid CF-4/-5/-6/-7/-8/-9 CF-4/-5/-6/-7/-8/-9 CF-6/-7/-8/-9
Kanamycin∗ CF-4/-5/-6/-7/-8/-9 CF-7/-8/-9 CF-6/-7/-8/-9
∗All E. coli isolates had intermediate resistance to cefoxitin, ceftazidime, and kanamycin.
0.125-1 휇g/mL, respectively; therefore, parent isolates were
susceptible to these 2 antimicrobial agents. The MIC values
of CF and CAZ against induced isolates are shown (Table 2).
After exposure to sub-MIC of CF, 8, 7, and 6 isolates that were
derived from E4, E11, and E21, respectively, were resistant to
CF. After exposure to sub-MIC of CAZ, 6, 8, and 6 isolates
derived from E4, E11, and E21, respectively, were resistant to
CAZ.
3.2.Morphological Characteristics. Morphological character-
istics of E. coli isolates recovered after induction with CF
were similar to those of their parent isolates (Figures 1 and
2). However, morphological changes on blood agar were
observed in 17 isolates recovered after induction with CAZ
compared to their parent isolates. Of those isolates, 6, 5,
and 6 were derived from E4, E11, and E 21, respectively.
Colonies of those isolates were smaller after 24 h incubation
at 37∘C and became sticky and were therefore difficult to
retrieve (Figure 1). Also, cells of all isolates recovered after
inductionwithCAZwere elongated, with a filamentous shape
(Figure 2).
3.3. Antimicrobial Susceptibility Proﬁles. Among CF-induced
isolates, 17, 13, and 13 developed intermediate resistance to
cefoxitin, ceftazidime, and kanamycin, respectively, whereas
no isolate was resistant to these 3 antimicrobial agents
(Table 3).Of isolates with intermediate resistance to cefoxitin,
7, 5, and 5 were derived from E4, E11, and E21, respectively. Of
isolates with intermediate resistance to kanamycin, 6, 3, and 4
were derived from E4, E11, and E21, respectively. In addition,
6 and 4 isolates derived from E4 and E21 were resistant
to ampicillin and amoxicillin/clavulanic acid, respectively,
whereas 7 and 6 isolates derived from E11 became resis-
tant to ampicillin and amoxicillin/clavulanic acid. All CF-
induced isolates were susceptible to cefepime, gentamicin,
and amikacin. Parent isolates remained susceptible to all
tested antimicrobial agents.
Among CAZ-induced isolates, all were resistant to CF.
Nineteen isolates became resistant to cefoxitin, of which 6,
7, and 6 were derived from E4, E11, and E21, respectively.
Only 1 CAZ-induced isolate (CAZ-1 derived from E4) was
susceptible to ampicillin and amoxicillin/clavulanic acid. All
isolates derived from E4 and E21 became intermediate to
kanamycin, whereas CAZ-1 from E11 remained susceptible
(Table 4). All CAZ-induced isolates were susceptible to
cefepime, gentamicin, and amikacin. Parent isolates were
susceptible to all tested antimicrobial agents.
3.4. ESBL Production and ESBL-Related Genes. The differ-
ence in diameters between the inhibition zone of cefotaxime
and cefotaxime plus clavulanic acid was < 5 mm for all
induced isolates, except 5 derived from E4 (CAZ-5 to CAZ-
9). The difference of the zone diameters for those 5 CAZ-
induced isolates was ≥ 5 mm (Figure 3), which was an
indication for ESBL production by those isolates. However,
none of the tested ESBL-encoding genes were detected in
ESBL-producing isolates.
3.5. Endotoxin Release. Endotoxin release increased with
time (2, 4, 6, 8, and 10 h) for 2 treatment types and control
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Figure 1: Colony morphology of parent Escherichia coli and antibiotic-induced isolates recovered after induction (24 h). (a), (d), and (g) were
parent strains; (b), (e), and (h) were cefalotin-induced isolates; and (c), (f), and (i) were ceftazidime-induced isolates.
(P < 0.0001). The amount of endotoxin released by CAZ-
induced mutants differed from the parent E. coli isolates (P
< 0.001). Therefore, CAZ at sub-MIC increased release of
endotoxin from induced E. coli mutants when compared to
parent strains (Figure 4). However, the amount of endotoxin
released by CAZ mutants was not associated with generation
of the isolate (P = 0.94). There was no difference in amount
of endotoxin released at the same time point for CF-induced
mutants compared to parent E. coli isolates (P = 0.70), nor
did endotoxin release by CF-mutants vary by generation (P =
0.79). Therefore, CF at sub-MIC did not increase endotoxin
release, compared to parent isolates, at any time point.
Both antibiotic type and incubation time were associated
with endotoxin release (Table 5; Figure 4). All treatments
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Figure 2: Cell morphology of parent Escherichia coli and isolates recovered after induction with antibiotics. Cells were subjected to Gram-
staining and examined with an optical microscope (1000×). (a), (d), and (g) were parent strains; (b), (e), and (h) were cefalotin-induced
isolates; and (c), (f), and (i) were ceftazidime-induced isolates.
followed similar release patterns over time, starting with a
high rate of endotoxin release that plateaued after 6 h.
4. Discussion
This was apparently the first study to characterize changes
in morphology, antimicrobial resistance, and endotoxin
releasing of E. coli isolated from bovine CM under persistent
exposure to CF and CAZ at sub-MIC. In this study, sub-MIC
in vitro exposure of CF andCAZ resulted not only in failure of
killing E. coli, but also in increased antimicrobial resistance.
In addition, exposure to CAZ led to generation of more
virulent strains of E. coli. Choice of antibiotic, administration
route, and treatment duration are determined by many
BioMed Research International 7
Table 4: Antimicrobial susceptibility profiles of the Escherichia coli isolates recovered after induction with ceftazidime.
Resistant E. coli isolates
Antimicrobial Derived from E4 Derived from E11 Derived from E21
Cefalotin CAZ-1/-2/-3/-4/-5/-6/-7/-8/-9 CAZ-1/-2/-3/-4/-5/-6/-7/-8/-9 CAZ-1/-2/-3/-4/-5/-6/-7/-8/-9
Cefoxitin CAZ-4/-5/-6/-7/-8/-9 CAZ-3/-4/-5/-6/-7/-8/-9 CAZ-4/-5/-6/-7/-8/-9
Ampicillin CAZ-2/-3/-4/-5/-6/-7/-8/-9 CAZ-1/-2/-3/-4/-5/-6/-7/-8/-9 CAZ-1/-2/-3/-4/-5/-6/-7/-8/-9
Amoxicillin/clavulanic acid CAZ-2/-3/-4/-5/-6/-7/-8/-9 CAZ-1/-2/-3/-4/-5/-6/-7/-8/-9 CAZ-1/-2/-3/-4/-5/-6/-7/-8/-9
Kanamycin∗ CAZ-1/-2/-3/-4/-5/-6/-7/-8/-9 CAZ-2/-3/-4/-5/-6/-7/-8/-9 CAZ-1/-2/-3/-4/-5/-6/-7/-8/-9
∗All E. coli isolates had intermediate resistance to kanamycin.
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Figure 3: Extended spectrum beta-lactamase (ESBL) production of isolates recovered after induction by cefalotin (a) or ceftazidime (b).
Isolates at various generations are listed on the X-axis. Differences were calculated as diameter of the inhibition zone of ceftazidime plus
clavulanic acid subtracted from their respective single discs. An isolate was designated an ESBL producer if the difference was > 5 mm.
factors [23], which makes the choice of treatment strategy
relatively subjective or arbitrary. Based on our findings, we
inferred that prudent usage of antibiotics should be proposed
when treating CM, particularly if caused by E. coli.
After continuous sub-MIC exposure to CF or CAZ, iso-
lates became increasingly resistant toCF orCAZ, respectively.
Bacteria can quickly develop resistant phenotypes under
persistent cephalosporin stress [24]. In addition, several
isolates became resistant to 훽-lactams (CF, cefoxitin, CAZ,
ampicillin, and amoxicillin/clavulanic acid) after exposure to
either CF or CAZ. Similarly, bovine E. coli strains isolated
from cows treated with ceftiofur became resistant to cefa-
zoline, whereas strains not previously exposed to ceftiofur
remained susceptible [25]. Resistance of E. coli strains to
multiple antimicrobials could result in failure of mastitis
therapy and is a serious threat to human and animal health.
Mutants of Pseudomonas aeruginosa isolated from humans
became resistant to various antimicrobials after induction
with ceftazidime [26]. Resistance to vancomycin increased
in Staphylococcus aureus isolates, accompanied with mor-
phologic alteration, after continuous exposure to ceftazidime
[27]. Results of these 2 studies were in accordance with our
findings.
Colonies of E. coli isolates recovered after induction
with CAZ were smaller and stickier than the parent iso-
late. This was in accordance with a previous study that
growth of Bacteroides thetaiotaomicron isolates was slower
after exposure to cefoxitin [28]. In our study, bacterial
cells became extensively elongated (filamentation), consis-
tent with several E. coli strains that become filamentous
after exposure to various antimicrobial agents [18, 19, 29].
Escherichia coli readily became filamentous in shape when
exposed to cephalosporins [29]. Effects of antibiotics on
bacterial morphology or survival depend on both type and
dosage [19, 30]. Antibiotics can kill bacteria by acting on
penicillin-binding proteins (PBPs) [31]. There are 3 kinds of
PBPs: PBP1, PBP2, and PBP3. Various types and dosages of
antibiotics could bind to different PBPs, whichmay result in a
morphology change of bacteria [30]. A high concentration of
CAZ candestroy bacteria quickly by inhibiting PBP1, whereas
the same antibiotic administered at lower concentrations can
lead to filamentation of bacteria [32]. In the present study,
filamentation of isolates at 6th and later generations of growth
was weaker than during earlier generations; perhaps induced
isolateswere already adapted to antimicrobial exposure. It has
been reported that the filamentous bacteria return to a typical
8 BioMed Research International
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Figure 4: Endotoxin release of Escherichia coli isolates included in the study at various time points (0, 2, 4, 6, 8, and 10 h).
Table 5: Results of a linear mixed regression model for log endotoxin release (log of EU/mL) by Escherichia coli after exposure to cefalotin
(CF) or ceftazidime (CAZ).
Parameter Estimate SEM P-value
Parent isolates (Ref.)∗ 6.07 0.11 <0.001
CAZ 0.50 5.01 x 10−3 <0.001
CF 0.02 5.01 x 10−3 0.699
Interactions†
CAZ x generation 3.78 x 10−4 5.23 x 10−3 0.942
CF x generation 1.39 x 10−3 5.23 x 10−3 0.791
Time (h) 1.60 0.02 <0.001
Time2 (h2) -0.16 5.39 x 10−3 <0.001
Time3 (h3) 0.01 3.54 x 10−4 <0.001
Between-replicate variance 0.03 0.16
Endotoxin release was measured at various time points (2, 4, 6, 8, and 10 h) and resistance was induced over varying numbers of generations.
∗Baseline to which other samples were compared was a parent isolate (generation 0)
†Interactions were not created with the parent isolate as there was only 1 generation
bacillus shape after antibiotic removal, so filamentation was
temporary [33]. Interestingly, isolates recovered after induc-
tion with CF did not undergo obvious changes in colonial
and bacterial morphology. Presumably, CF bound to different
PBPs, which did not make the cell filamentous.
In this study, 5 isolates recovered after induction with
CAZ produced ESBL phenotype, while no ESBL-associated
genes were detected in these isolates. One potential rea-
son for this discrepancy might be that we were unable to
detect the genes that were responsible for ESBL production.
In the present study, we only tried to detect common
ESBL-encoding genes, as described [21, 22]. Nevertheless,
other ESBL-encoding genes not targetted in this study may
have been responsible for production of ESBL [34].Moreover,
there might be a misinterpretation of data, since the differ-
ence of 4 of 5 isolates was just at the threshold (5 mm) to
detect ESBL phenotypes.
Release of endotoxins from the disrupted E. coli cell
walls could cause a serious inflammatory reaction in an
infected udder [35]. Besides, high endotoxin in ingested
infant formula milk might cause neonatal bacteraemia and
endotoxemia, especially in neonates with immature innate
BioMed Research International 9
immune systems [8]. In our study, all parent and induced
isolates released more endotoxin when incubation was pro-
longed, which was in accordance with reports that bacteria
released more endotoxin in induction period by antibiotics
due to overexpression or shedding at higher speed from cell
wall [36, 37]. Increased release of endotoxin from isolates
recovered after inductionwithCAZmayhave been associated
with filamentation of E. coli after exposure to CAZ [19,
30]. Filamentation of cells could increase the surface of the
cell wall with a higher endotoxin release from cell wall
and, therefore, a higher releasing speed. In contrast, isolates
recovered after induction with CF did not produce more
endotoxin than parent isolates, whichmay be associated with
less morphological changes in these isolates.
Although a series of phenotypic changes (morphology,
antimicrobial resistance, and endotoxin releasing capability)
were observed in the current study, mechanism of bacteria’s
acquired resistance after exposure to the antibiotics should
be further clarified. Therefore, a study including whole-
genome sequencing and analysis of acquired mutations
should be conducted, to provide insights regarding the origin
of observed resistance.
5. Conclusions
After exposure to subminimumconcentrations of CF orCAZ,
parent E. coli CM isolates underwent a series of changes
related to morphology, antimicrobial resistance pattern, and
endotoxin release. Several isolates recovered after induction
had higher resistance to CF, CAZ, and some other commonly
used antimicrobials. Moreover, several isolates recovered
after induction with CAZ had slower growth on blood
agar, became filamentous, and released more endotoxin.
Therefore, we inferred that there shoud be prudent use
of cephalosporins, especially those that belong to the 3rd
generation, for treatment of bovine mastitis caused by E.
coli. Such treatment would increase potential risk to formula
fed neonates if the milk with endotoxin was processed into
powdered infant formula milk.
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